Baolingbao Biology Co.,Ltd.

blb-cn.com

BAOLINGBAO BIOLOGY CO.,LTD is a leading Chinese producer of starch-based health and food ingredients. The company mainly provide erythritol, isomaltitol L-glutamine, isomaltooligosaccharide-900/500, malto-oligosacchardie, xylo-oligosaccharide, fructo-oligosaccharide, indigestible dextrin, polydextrose, beta-cyclodextrin, high fructose corn syrup, dextrose monohydrate, liquid glucose,Corn gluten meal and so on.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

CHARLES RIVER EXPANDS STRATEGIC PARTNERSHIP WITH SAMDI TECH

Charles River Laboratories International, Inc. | January 28, 2022

news image

Charles River Laboratories International, Inc. announced the expansion of their strategic partnership with Chicago, Illinois-based SAMDI Tech, Inc. Under the existing partnership, established in 2018, SAMDI Tech clients have access to Charles River’s collection of lead-like compounds for high-throughput screening. The expanded agreement establishes Charles River as the exclusive partner for the promotion of SAMDI Tech’s technology. This partnership will provide Charles River’s ...

Read More

MedTech

SORRENTO ANNOUNCES COVISTIX COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST DETECTS THE OMICRON VARIANT

Sorrento Therapeutics, Inc. | December 28, 2021

news image

Sorrento Therapeutics, Inc. announced that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and its other major VoCs such as the delta and delta-plus strains. The COVISTIX detection levels were similar for all variants. The ease of use and timely detection of Omicron infection was demonstrated by a recent case report of a Mexico patient infected with the Omicron variant detected fi...

Read More

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

news image

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More

INTRAVACC'S CANDIDATE RSV VACCINE DEMONSTRATES SAFETY IN PHASE I TRIAL

Intravacc | August 18, 2020

news image

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine, of a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The vaccine showed excellent induction of immunogenicity after nasal administration to healthy adult volunteers (18-50 years). In addition, the Live Attenuated Vaccine (LAV), constructed with reverse genetics, appears to be safe and well-tolera...

Read More
news image

Industrial Impact

CHARLES RIVER EXPANDS STRATEGIC PARTNERSHIP WITH SAMDI TECH

Charles River Laboratories International, Inc. | January 28, 2022

Charles River Laboratories International, Inc. announced the expansion of their strategic partnership with Chicago, Illinois-based SAMDI Tech, Inc. Under the existing partnership, established in 2018, SAMDI Tech clients have access to Charles River’s collection of lead-like compounds for high-throughput screening. The expanded agreement establishes Charles River as the exclusive partner for the promotion of SAMDI Tech’s technology. This partnership will provide Charles River’s ...

Read More
news image

MedTech

SORRENTO ANNOUNCES COVISTIX COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST DETECTS THE OMICRON VARIANT

Sorrento Therapeutics, Inc. | December 28, 2021

Sorrento Therapeutics, Inc. announced that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and its other major VoCs such as the delta and delta-plus strains. The COVISTIX detection levels were similar for all variants. The ease of use and timely detection of Omicron infection was demonstrated by a recent case report of a Mexico patient infected with the Omicron variant detected fi...

Read More
news image

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More
news image

INTRAVACC'S CANDIDATE RSV VACCINE DEMONSTRATES SAFETY IN PHASE I TRIAL

Intravacc | August 18, 2020

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine, of a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The vaccine showed excellent induction of immunogenicity after nasal administration to healthy adult volunteers (18-50 years). In addition, the Live Attenuated Vaccine (LAV), constructed with reverse genetics, appears to be safe and well-tolera...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us